A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer.

The Oncologist
Xiao X WeiCharles J Ryan

Abstract

In abiraterone- and/or enzalutamide-refractory metastatic castration-resistant prostate cancer (mCRPC) patients, selinexor led to prostate-specific antigen and/or radiographic responses in a subset of patients, indicating clinical activity in this indication.Despite twice-a-week dosing and maximal symptomatic management, selinexor was associated with significant anorexia, nausea, and fatigue in mCRPC patients refractory to second-generation anti-androgen therapies, limiting further clinical development in this patient population.This study highlights the challenge of primary endpoint selection for phase II studies in the post-abiraterone and/or post-enzalutamide mCRPC space. Selinexor is a first-in-class selective inhibitor of nuclear export compound that specifically inhibits the nuclear export protein Exportin-1 (XPO-1), leading to nuclear accumulation of tumor suppressor proteins. This phase II study evaluated the efficacy and tolerability of selinexor in patients with metastatic castration-resistant prostate cancer (mCRPC) refractory to abiraterone and/or enzalutamide. Fourteen patients were enrolled. Selinexor was initially administered at 65 mg/m2 twice a week (days 1 and 3) and was subsequently reduced to 60 mg flat dose...Continue Reading

References

Jan 21, 2004·Nature Reviews. Cancer·Tweeny R KauPamela A Silver
May 27, 2011·The New England Journal of Medicine·Johann S de BonoUNKNOWN COU-AA-301 Investigators
Aug 17, 2012·The New England Journal of Medicine·Howard I ScherUNKNOWN AFFIRM Investigators
Dec 12, 2012·The New England Journal of Medicine·Charles J RyanUNKNOWN COU-AA-302 Investigators
Jun 3, 2014·The New England Journal of Medicine·Tomasz M BeerUNKNOWN PREVAIL Investigators
Mar 2, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Albiruni R Abdul RazakAmit Mahipal
May 18, 2016·Prostate Cancer and Prostatic Diseases·E S AntonarakisJ Luo
Jul 28, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mrinal M GounderAlbiruni Ryan Abdul Razak
Aug 11, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas B AlexanderJeffrey E Rubnitz
Nov 1, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Thomas VercruysseDirk Daelemans

❮ Previous
Next ❯

Citations

May 8, 2018·Cancers·Irfana MuqbilRamzi M Mohammad
Jan 21, 2020·Expert Opinion on Pharmacotherapy·Klaus PodarSundar Jagannath
Nov 9, 2018·International Journal of Hematologic Oncology·Chetasi Talati, Kendra L Sweet
Jun 17, 2020·Leukemia & Lymphoma·Janek S WalkerRosa Lapalombella
Nov 25, 2018·Cells·Friederike K Kosyna, Reinhard Depping
Jun 4, 2020·Journal of Hematology & Oncology·Nancy G Azizian, Yulin Li
Aug 21, 2019·Drugs·Yahiya Y Syed
Nov 12, 2020·Nature Reviews. Clinical Oncology·Asfar S AzmiRamzi M Mohammad

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01637402
NCT01949337

Related Concepts

Related Feeds

Anorexia Nervosa

Anorexia nervosa (AN) is a psychiatric condition characterized by severe weight loss and secondary problems associated with malnutrition. Here is the latest research on AN.

Autophagy & Aging: Inhibitors

The feed focuses on the role of nuclear export inhibitors and their effect on autophagy and the aging process.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Albiruni Ryan Abdul RazakAmit Mahipal
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Mrinal M GounderAlbiruni Ryan Abdul Razak
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Dan T VoglA Keith Stewart
© 2022 Meta ULC. All rights reserved